Reasons Lilly Stock: 5 Key Upsides Investors Should Watch
This deep dive looks at why Lilly stock may be a standout pick for growth-focused investors. From a dominant obesity ...
GLP-1
This tag page compiles 4 articles on GLP-1 trends, pricing, and weight-loss stock impacts, helping you understand how drug costs and market moves affect personal finances.
41 articles
Invesco's RSPH PJP: Which Health Care ETF Is Best?
Two Invesco health care ETFs offer different paths to play the GLP-1 revolution. This guide breaks down how invesco's...
Reasons Lilly Stock Like There’s No Tomorrow: A Bold Buy
Seeking a stock with growth, resilience, and optionality? This article lays out three strong reasons to consider Lill...
Lilly Novo Nordisk Battle Intensifies as Obesity Drugs Surge
Eli Lilly's Q1 2026 results slam the lid on the GLP-1 duopoly's early calm, with Lilly’s revenue exploding and Novo N...
Wegovy Pill Still Dominating GLP-1 Market, Analysts Say
Wegovy continues to lead the U.S. GLP-1 market despite Eli Lilly's Foundayo launch. Investors are weighing uptake, pa...
Mayim Bialik Says GLP-1: Financial Realities Explained
A high-profile health story meets everyday budgeting: how GLP-1 treatments can impact your finances, with lessons fro...
Prediction: Lilly Will Reach $1,200 in 2026 — Investment Thesis
Eli Lilly’s GLP-1 drugs are redefining growth in obesity and diabetes treatment. This article lays out why the stock ...
Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Reasons Lilly Remains a Buy: 3 Strong Drivers for Investors
Investors are eyeing Lilly for its resilient growth, strong pipeline, and shareholder-friendly strategy. This piece b...
CVS to Cover Lilly’s GLP-1 Medications, Expanding Access
CVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...
Novo Nordisk Beating Lilly in Obesity Pill Market: What It Means for Investors
Novo Nordisk is gaining ground on Lilly in the obesity pill market. This article breaks down the drivers, the competi...
Viking Therapeutics Takeover Target in Biotech Investing?
Investors increasingly ask whether Viking Therapeutics could become a takeover target. This article breaks down why b...